Bioethics, Ltd. is a shell company that conducts no active business operations and is seeking business opportunities for acquisition or participation by the Company. The Company is formed for the purpose of entering a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The Company has not selected any specific business combination target and has not, nor has anyone on its behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. The Company did not generate revenue.

Employees

Sector

Investment Holding Companies

More about the company

Income Statement and Estimates

More financial data

Market Closed - OTC Markets Other stock markets 10:56:45 2025-11-03 EST			5-day change	1st Jan Change
0.005100 ^USD	-99.73%		-.--%	-

25-08-13	Bioethics, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-08-12	Bioethics, Ltd. Auditor Raises 'Going Concern' Doubt	CI

Market Cap	18.36K 15.9K 14.82K 13.63K 25.74K 1.75M 26.03K 174K 68.37K 874K 68.96K 67.44K 2.89M	P/E 2023	-2.46x	P/E 2024	-9.7x
Enterprise Value	589K 510K 476K 438K 826K 56.04M 835K 5.59M 2.19M 28.04M 2.21M 2.16M 92.87M	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	10.98%	Yield 2023 *	-	Yield 2024	-

25-08-13	Bioethics, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-08-12	Bioethics, Ltd. Auditor Raises 'Going Concern' Doubt	CI
24-11-19	Bioethics, Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-08-19	Bioethics, Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-06-25	SILQ Technologies Corporation entered into a non-binding letter of intent to acquire Bioethics, Ltd. in a reverse merger transaction.	CI
24-05-20	Bioethics, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
24-04-30	Bioethics, Ltd. Appoints Doug Morris as A Member of Board of Directors	CI
24-04-11	Bioethics, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-04-10	Bioethics, Ltd. Auditor Raises 'Going Concern' Doubt	CI
23-11-14	Bioethics, Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
23-08-09	Bioethics, Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
23-05-19	Bioethics, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
23-04-17	Bioethics, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	CI

24-06-26	Bioethics : Proposed Transaction Form 8 K	PU
23-04-17	BIOETHICS LTD Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	AQ
22-11-21	BIOETHICS LTD Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
22-08-15	BIOETHICS LTD Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
22-05-23	BIOETHICS LTD Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ

Bioethics, Ltd. Stock

Stocks

BOTH

US09059E2090

Investment Holding Companies

Valuation: Bioethics, Ltd.

Chart: Bioethics, Ltd.

Latest news : Bioethics, Ltd.

Press Releases: Bioethics, Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Bioethics, Ltd.

Shell Companies

Financials

Company Profile

Income Statement and Estimates

Manager	Title	Age	Since
Mark Scharmann CEO	Chief Executive Officer	67	2015-07-23
Douglas Morris PRN	Corporate Officer/Principal	70	2024-04-25

Director	Title	Age	Since
Mark Scharmann BRD	Director/Board Member	67	2015-07-23
Elliott N. Taylor BRD	Director/Board Member	67	2019-12-18
Douglas Morris BRD	Director/Board Member	70	2024-04-25

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOETHICS, LTD.	-99.73%	-.--%	-99.59%	-97.57%	18.36K
BOXABL INC.	-1.93%	-8.03%	-54.06%	-	13.38B
FREENOME, INC.	+11.61%	+10.83%	+5.49%	-	1.23B
CHURCHILL CAPITAL CORP XI	+3.44%	+17.83%	-	-	858M
CENTIEL AG	+5.61%	+11.51%	+308.43%	-65.58%	647M
DRUGS MADE IN AMERICA ACQUISITION II CORP.	0.00%	-0.10%	-	-	644M
CHURCHILL CAPITAL CORP XII	+0.52%	+0.80%	-	-	604M
BAIN CAPITAL GSS INVESTMENT CORP.	0.00%	-0.20%	-	-	596M
CANTOR EQUITY PARTNERS IV, INC.	-0.33%	-0.52%	-	-	595M
Average	-8.98%	+3.33%	+40.07%	-81.58%	2.06B
Weighted average by Cap.	-0.26%	+12.33%	-33.88%	-65.58%

	2023	2024
Net sales	-	-
Net income	-97.15K -84.14K -78.43K -72.14K -136K -9.24M -138K -922K -362K -4.62M -365K -357K -15.31M	-177K -153K -143K -131K -248K -16.83M -251K -1.68M -659K -8.42M -665K -650K -27.88M
Net Debt	443K 383K 357K 329K 620K 42.09M 627K 4.2M 1.65M 21.06M 1.66M 1.63M 69.74M	571K 495K 461K 424K 800K 54.3M 809K 5.42M 2.13M 27.17M 2.14M 2.1M 89.98M

1 year	0.01	0.01
3 years	0.01	3.6
5 years	0.01	3.6
10 years	0.01	16